In a recent study, researchers looked at how the body’s immune system reacts to pleural mesothelioma. The results were released in Pathobiology. Researchers looked at samples from 60 pleural mesothelioma patients to study immune cells in the tumor area. They used markers to identify cell types and their impact on[…]
Pleural Mesothelioma
Finding Mesothelioma in Situ
Pleural mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. It mainly affects the pleura, the thin membrane that surrounds the lungs. Many people do not know their mesothelioma is from asbestos exposure because it can take decades from the time of exposure to be diagnosed with[…]
Surgery and Improved Mesothelioma Survival
Pleural mesothelioma is a rare and aggressive cancer. The cancer with a poor prognosis is mainly caused by asbestos. Surgery is an important part of treating pleural mesothelioma, but the impact of surgery on patients’ survival is unclear and sparking debate. A recent study was presented at the World Conference[…]
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease ((RIOT 4A))
Primary Outcome Measures Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device To demonstrate the safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) to study patients Secondary Outcome Measures To document changes in the pleural[…]
Opdivo and Yervoy Before and After Surgery and a New Blood Test are Improving Mesothelioma Treatment
Researchers are reporting promising results for people with mesothelioma who can have surgery. One researcher tested immunotherapy before and after surgery while the other researcher studied a blood test that helps doctors detect mesothelioma earlier than scans. Doctors at several cancer centers, including Johns Hopkins, ran an early clinical trial[…]
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Primary Outcome Measures Disease-related Symptom Burden 3 Months After Partial Pleurectomy (Surgery) Secondary Outcome Measures Quality of Life of Study Participants Who Have Undergone Partial Pleurectomy (Surgery) Rate of Complications after Partial Pleurectomy (Surgery) Time to Resumption of Systemic Therapy Overall Survival of Study Participants Who Have Undergone Partial Pleurectomy[…]
Mesothelioma Diagnosis
Mesothelioma is a rare and hard to diagnose cancer. There are many challenges patients and caregivers must face once someone is diagnosed with mesothelioma. There are expert guidelines that were recently updated by the International Mesothelioma Interest group. The group provides insights into mesothelioma’s diagnosis, which is incredibly valuable for[…]
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Empyema Challenges After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is very tough to treat. Surgery is one part of multimodal therapy that aims to remove as much cancer as possible. Surgery is a very useful tool in the treatment of mesothelioma, but after surgery, complications can occur. One complication can be[…]
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NECIM)
Primary Outcome Measures To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma. Secondary Outcome Measures Toxicity of the neoadjuvant double chemotherapy / double immunotherapy regimen and[…]
Skip to content